Category: Replacement Heart Valves
Heart Valves
Transcatheter aortic valve implantation proves successful in reinforcing failed valve prosthetics, but researchers warn against making it a common practice.
Although patients may benefit from having a failed aortic valve prosthetic reinforced via transcatheter aortic valve implantation, researchers warned against making the procedure a common practice.
Boston Scientific's Lotus TAVI system minimizes leakage in an early trial, St. Jude Medical gains on a Goldman upgrade and the SEC closes a probe of Zoll's Middle East sales just ahead of $2.3B Asahi merger.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Boston Scientific's Lotus transcatheter aortic valve implantation system proves to minimize paravalvular leakage after successful implantation in patients with severe symptomatic aortic stenosis who are too sick to undergo open-heart surgery.
Boston Scientific's (NYSE:BSX) Lotus transcatheter aortic valve implantation system fared well in an early feasibility study in patients with severe symptomatic aortic stenosis who were to sick to undergo open-heart surgery.
Medtronic's CRM layoffs may be a sign of a prolonged slump; Johnson & Johnson might be eyeing Edwards or St. Jude; Edwards wins CMS Medicare coverage for its Sapien TAVI system; Masimo CEO Kiani tells us why the med-tech industry should protect its young; GOP govs ask Senate and House leaders to kill the medical device tax; MassDevice.com looks at the most talked about device makers in April; and Siemens reveals probes into Russian payments and its diagnostics business.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
The Centers for Medicare & Medicaid Services affirm coverage for transcatheter aortic valve implantation systems, such as Edwards Lifesciences' landmark Sapien device, with a few caveats.
Shares of Edwards Lifesciences (NYSE:EW) jumped a few points as the Centers for Medicare & Medicaid affirmed coverage for the med-tech titan's landmark Sapien transcatheter aortic valve implantation system.
EW shares jumped 2.2% to $84.78 in after hours trading as of about 6 p.m. today.
A Senate panel adds safety measures to the FDA user fee act, NASDAQ halts trading in HeartWare shares ahead of an FDA panel vote and Edwards' Sapien sales spike 67% during the device's 1st quarter on U.S. market.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Shares of Edwards Lifesciences jump 4% in after-hours trading after the company posts a 67% spike in Q1 Sapien transcatheter heart valve sales.
Shares of Edwards Lifesciences (NYSE:EW) got a little boost on Wall Street after the company posted a 67% spike in Sapien sales during its 1st quarter.
The Irvine, Calif.-based med-tech titan posted $459.2 million in sales during the 3 months ended March 31, a 13.5% increase from he $404.5 million in revenues posted during the same period last year.
